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Abstract
Background: Canine atopic dermatitis (AD) is a common inflammatory skin disease associated with defects in the
epidermal barrier, particularly in West Highland white terriers (WHWTs). It shares many similarities with human AD,
and so may be a useful animal model for this disease. Epidermal dysfunction in human AD can be caused by
mutations in the gene encoding the epidermal protein filaggrin (FLG) and, in some atopic patients, be associated
with altered FLG mRNA and protein expression in lesional and/or non-lesional skin. In experimental models of
canine AD, mRNA expression of the orthologous canine filaggrin gene may be reduced in non-lesional skin
compared with healthy controls. However, there is no published data on canine filaggrin mRNA expression in the
skin of dogs with naturally-occurring AD. Hence, the aim of this pilot study was to develop a reverse transcriptase
real-time PCR assay to compare filaggrin mRNA expression in the skin of atopic (n = 7) and non-atopic dogs (n =
5) from five breeds, including eight WHWTs.
Findings: Overall, filaggrin mRNA expression in non-lesional atopic skin was decreased compared to non-lesional
non-atopic skin (two fold change); however this difference was only statistically significant in the subgroup of
WHWTs (P = 0.03).
Conclusions: Although limited by the small sample size, these results indicate that, comparable to some cases of
human AD, altered filaggrin mRNA expression may exist in the skin of some atopic dogs with naturally-occurring
disease. Additional studies, including larger sample numbers, will be necessary to confirm this finding and to
investigate whether mutations in the filaggrin gene exist and contribute to epidermal lesions of AD in dogs.
Findings
Canine atopic dermatitis (AD) is a common inflamma-
tory allergic skin disorder and results from a combina-
tion of genetic and environmental factors [1]. Changes
in the structure, function and composition of the epider-
mis are present in atopic dogs compared with normal
dogs, and may predispose to the development of the dis-
ease by enhancing percutaneous absorption and antigen
presentation to the immune system [2]. Accordingly,
mRNA expression studies have reported that genes
encoding for proteins having epidermal barrier functions
(e.g. loricrin, serine protease inhibitor kazal type-5) were
either up-regulated or down-regulated in lesional and/or
non-lesional skin of atopic dogs compared with normal
dogs [3,4]. As AD in West Highland white terriers
(WHWTs) is particularly common [5] and is usually a
severe phenotype [6], a highly permeable epidermal bar-
rier in these dogs with marked changes in genes encod-
ing epidermal proteins may be expected to occur.
Many similarities exist between canine and human AD
[7]. In humans with AD, 25-50% of cases have been
reported to have defects in the epidermal protein filag-
grin leading to an impaired epidermal barrier, and pre-
disposing to development of the disease [8]. Filaggrin is
produced by proteolytic cleavage of profilaggrin, a pre-
cursor located within the keratohyalin granules, during
terminal differentiation of the epidermis [9]. Studies in
humans have showed filaggrin has several important
functions, including those of epidermal support, hydra-
tion, photoprotection and pH regulation [10]. Mutations
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in the human gene encoding profilaggrin (FLG) can
result in loss of protein function, disruption of the nor-
mal epidermal barrier, and promotion of allergen pene-
trance [11,12]. In some humans with AD, these
mutations may be associated with decreased immunos-
taining of the filaggrin protein in both lesional and non-
lesional skin [13,14]. On the other hand, changes in
FLG mRNA expression in human atopic skin are not so
clear [13,15-17]. The only study that has analysed
mRNA and protein expression simultaneously in human
atopic patients determined that the decrease in expres-
sion in lesional skin was mostly caused by inflammatory
sub-products (interleukins), and that the presence of
mutations in the FLG gene did not significantly affect
mRNA levels in non-lesional skin [13].
As in humans, studies using immunohistochemistry
(IHC) and immunofluorescent (IF) methods report
abnormalities in filaggrin protein expression in lesional
and non-lesional skin of some dogs with both naturally-
occurring and experimentally induced canine AD
[18-20]. These changes include decreased filaggrin pro-
tein expression in non-lesional atopic skin compared
with healthy dogs, and abnormalities in filaggrin protein
structure in the lesional and non-lesional epidermis of
some atopic dogs (e.g. altered IHC staining of protein
terminal domains, altered IF staining pattern following
allergen challenge). Such changes might suggest defects
in filaggrin protein maturation and are consistent with
22% of affected dogs having loss-of-function mutations
causing C-terminal truncation (as is reported in human
AD) [18]. Further, filaggrin protein abnormalities were
present in an atopic dog model prior to any allergen
challenge, suggesting a possible underlying genetic cause
[19].
The only pilot study investigating filaggrin mRNA
expression in an experimental model of canine AD
reported significant differences between atopic and non-
atopic Beagles, with atopic animals showing less filaggrin
mRNA expression before allergen challenge than healthy
controls [20]. However, the orthologous canine filaggrin
gene was not further investigated for mutations in these
dogs. Mutations in the filaggrin gene, if present in dogs
with AD, are likely to be breed-specific [21]. Further, in
certain breeds (e.g. WHWTs) any filaggrin mutations
could have a small effect size on the phenotype, and
thus not affect mRNA expression and/or cause obvious
structural/histopathological epidermal abnormalities
[22]. Thus, while canine filaggrin mRNA and protein
levels may be decreased in non-lesional skin of some
dogs with AD, this finding may be breed-specific and/or
not be detected in all dogs with naturally-occurring
disease.
The aim of this pilot study was to develop a real-time
quantitative (RT qPCR) assay for canine filaggrin, and to
investigate whether reported variations in this gene
mRNA and protein’s expression in atopic dogs were
reflected at the transcription level in dogs from different
breeds with naturally-occurring disease. Such data will
be useful in understanding the pathogenesis of this com-
mon canine disease which is also likely to be a useful
animal model of human AD.
Results
Filaggrin mRNA expression in canine AD lesional, non-
lesional and healthy skin
Filaggrin mRNA expression in non-lesional atopic skin
(median mean normalized expression (MNE) = 0.02,
range 0.01-0.04) was decreased compared with non-
lesional non-atopic skin (median MNE = 0.04, range
0.01-0.16) (Figure 1), with a two-fold change in median
values. However, this difference was not statistically sig-
nificant (Mann-Whitney P = 0.34). This result did not
change after removing from the analysis the two atopic
dogs that had anti-inflammatory and/or immunosup-
pressive medication prior to the skin biopsy.
When performing this analysis in WHWTs only (n =
8), the difference in filaggrin mRNA expression between
non-lesional atopic skin (median MNE = 0.04, range
0.02 to 0.07) and non-lesional non-atopic skin (median
MNE = 0.4, range 0.1 to 0.6), was more pronounced
(fold change of 10) and statistically significant (P =
0.03).
The effects of age, sex and breed on MNE levels in
non-lesional skin were also evaluated, since the dogs
were not matched for these variables. Unlike breed and
sex, age had a significant influence on MNE levels
(ANOVA adjusted P = 0.05). A robust regression model,
using iterated re-weighted least squares, was employed
to attenuate the effect of extreme observations from two
older dogs (Figure 2). Under this model, age was the
only influential predictor (b = 0.02, t = 2.42); however it
did not significantly change the estimates for the other
coefficients, including clinical status (b = -0.10, t =
-0.67). Hence, age did not significantly influence the dif-
ference in filaggrin mRNA expression between non-
lesional atopic skin and non-lesional non-atopic skin.
In the one atopic WHWT dog with a lesional skin
sample available, filaggrin mRNA expression (MNE =
1.32) was 59.8 times that measured in non-lesional skin
from the same dog (MNE = 0.02), and 3.3 times the
median MNE of healthy control skin.
Discussion
The present study found that filaggrin mRNA expres-
sion was reduced in non-lesional atopic skin in the dogs
with naturally-occurring AD compared to healthy con-
trols (Figure 1). However, the overall difference was not
statistically significant, suggesting that previous findings
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in atopic dog models may not be observed in all dogs
with natural disease. These results are in accordance
with observations in human atopic patients, where
mRNA FLG expression is not always altered or asso-
ciated with the presence of mutations and/or protein
abnormalities. Alternately, variations in canine filaggrin
mRNA levels could be specific to certain breed(s) or
individual dogs with AD, and subject to phenotypic par-
ticularities [23]. Thus, in the present study, the more
significant decrease in filaggrin mRNA expression
reported in non-lesional atopic skin in WHWTs com-
pared with atopic dogs in general could be due to varia-
tions in disease expression (e.g. differences in disease
pathogenesis; particularities of the epidermal barrier) or
by genetic influences (e.g. presence of filaggrin muta-
tions) in this breed. Finally, the findings of the present
study could be also attributable to the small number of
available samples and/or the presence of atypical dogs
in the experimental groups.
Unfortunately, only one sample from lesional atopic
skin was available for study. In human AD, filaggrin
protein expression can be decreased in lesional atopic
skin compared with non-lesional atopic skin [13,15], but
no significant difference is detected at the mRNA level
[14]. In the atopic dog model, filaggrin mRNA expres-
sion reportedly increased with time (and with the devel-
opment of skin lesions), following allergen challenge in
experimentally sensitized Beagles [20]. A study using
IHC to analyse filaggrin protein expression in skin from
dogs of different breeds with naturally-occurring AD,
reported an increased number and size of immature
profilaggrin granules in one lesional hyperplastic atopic
skin sample compared to non-lesional and healthy con-
trol skin [18]. Similarly, another study using IHC in
dogs reported intense filaggrin protein staining in ortho-
keratotic hyperplastic skin disorders [24]. Therefore, the
increase in filaggrin mRNA expression in our study
could be associated with secondary epidermal changes
occurring in lesional atopic skin (e.g. filaggrin up-regula-
tion during inflammatory processes), or with particulari-
ties in the biopsy site (e.g. higher filaggrin mRNA
expression in the abdominal skin). Further studies to
investigate filaggrin mRNA expression analysis in paired
lesional and non-lesional samples, including dogs with
Figure 1 Filaggrin mRNA expression in non-lesional skin of atopic and non-atopic dogs. Boxplot comparing filaggrin mRNA expression
(MNE.NL) in non-lesional skin of atopic and non-atopic dogs. The heavy bar is the median value, and the upper and lower limits of box are the
75th and 25th percentiles, with the bars extending to 1.5 times the interquartile range. The single square is the mean.
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AD and other inflammatory diseases, would be required
to evaluate the significance of this finding.
In this study, we also evaluated the effect of breed, age
and sex on the relative expression levels of the filaggrin
transcript. Although limited by the small number of par-
ticipating dogs in this analysis, age seemed to exert the
only significant influence on MNE levels, with older
dogs having higher expression (Figure 2). The effect of
age on filaggrin expression, if any, is not documented in
dogs. However, in humans, expression level of epidermal
proteins such as involucrin and keratin 17 is increased
in fetal skin compared to adult skin [25]. This could
indicate changes in the epidermal barrier structure and
composition with age may also exist in dogs and affect
filaggrin expression.
Real-Time qPCR may be a more sensitive method
than IHC or IF, and so more robust to the effects of
inflammation, proteolysis and other external influences
[26]. Nevertheless, conclusions from RT qPCR can be
limited by experimental challenges. In this particular
study, one reference gene (RPS19) recommended as sui-
table for RT qPCR in atopic and healthy canine skin in
a previous report [27], showed variable expression levels
and suboptimal amplification efficiency during the initial
optimization steps, and was thus removed from subse-
quent analyses.
Figure 2 Effect of age on filaggrin mRNA expression in non-lesional skin of atopic and non-atopic dogs. Scatter plot showing the
correlation between age of dogs (years) and filaggrin mRNA expression in non-lesional skin (MNE.NL) of atopic (red dots) and non-atopic (black
dots) dogs.
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Conclusions
This study showed no overall significant difference in
filaggrin mRNA expression in the non-lesional skin of
atopic and non-atopic dogs with natural disease. How-
ever, significant decrease in filaggrin mRNA levels was
detected when comparing non-lesional atopic skin with
control skin in a subgroup of atopic WHWTs, suggest-
ing specific changes in mRNA filaggrin expression may
exist in AD in different breeds. Evaluation of filaggrin
mRNA expression levels in a larger number of atopic
and non-atopic animals, complemented by protein
expression studies, histopathological and functional stu-
dies, and sequencing of gDNA in atopic dogs, would be
useful to clarify whether mutations in filaggrin exist and
contribute to the development of epidermal lesions in
atopic dogs.
Methods
Animals in the study
The University of Queensland Animal and Human Ethics
Committees approved this study. Seven dogs were diag-
nosed as having canine AD by a veterinary dermatologist,
using pre-defined diagnostic criteria [28]. Five healthy
dogs were selected as controls and had no history or clin-
ical symptoms of canine AD, pyoderma, aural disease,
pruritus, foot chewing or face rubbing, and no clinical
conditions likely to affect the immune system.
The atopic group was composed of seven dogs (three
females, mean age 4.8 years, range 1-9 years), including
five WHWTs, one Beagle and one Cavalier King Charles
Spaniel. The control group was composed of five dogs
(four females, mean age 8.2 years, range 1-12 years),
including three WHWTs, one German Shepherd and
one mixed breed. In 10 of the 12 dogs enrolled in the
study, 5/7 atopic and 5/5 non-atopic, any anti-inflamma-
tory and/or immunosuppressive medication, including
immunotherapy, was withdrawn at least 3 weeks prior
to skin biopsy. One atopic dog had received immu-
notherapy less than 3 weeks prior to skin biopsy, and
another atopic dog had topical corticosteroids applied
twice weekly.
Tissue collection
Six mm punch (ZebraVet QLD Pty. Ltd., Sherwood,
QLD, Australia) biopsies were obtained, induced under
general anaesthesia with intravenous alfaxalone
(Alfaxan®, Jurox Pty Ltd., Rutherford, NSW, Australia)
and maintained with isoflurane inhalation (I.S.O. Inhala-
tion Anaesthetic, Veterinary Companies of Australia Pty.
Ltd., Marayong, NSW, Australia). Alternately, dogs were
sedated with intravenous alfaxalone and/or local prilo-
caine (Bomac® Prilocaine Local Anaesthetic, Intervet
Pty. Ltd., Bendigo, VIC, Australia) anaesthesia was used.
In one dog, punch biopsy samples were obtained 5 min
after euthanasia for reasons unrelated to skin disease or
this study, with Pentobarbital sodium (Lethabarb®
Euthanasia Injection, Virbac Pty. Ltd., Crookwell, NSW,
Australia). In 6/7 atopic dogs, one sample was obtained
from clinically unaffected skin on the dorsal neck. In
the remaining atopic dog, an extra sample was obtained
from lesional skin of the right abdomen (erythematous
papule of approximately 1 cm diameter). This lesion
was identified as a primary lesion by the veterinary der-
matologist performing the biopsy, therefore no lichenifi-
cation or hyperplasia was present. In 5/5 healthy dogs
one sample was collected from clinically unaffected skin
on the dorsal neck. After collection, all samples were
immediately immersed in RNAlater™ RNA stabilization
Reagent (QIAGEN Pty. Ltd., Doncaster, VIC, Australia)
and stored at -80°C.
RNA isolation and cDNA synthesis
RNA from skin samples was isolated using Trizol
reagent® (Invitrogen Pty, Mulgrave, VIC, Australia),
according to the manufacturer’s instructions, followed
by RNase-free DNase I treatment (Invitrogen Pty, Mul-
grave, VIC, Australia) to remove any genomic DNA.
Messenger RNA quality and concentration were ana-
lyzed spectrophotometrically (NanoDrop Technologies,
Wilmington, DE, USA). One microgram of total RNA
was reverse transcribed into cDNA using Reverse Tran-
scription System (Promega, Alexandria, NSW, Austra-
lia), according to the manufacturer’s instructions, and
stored at -80°C until use.
Quantitative real-time reverse transcription PCR
At the time of the study, the canine orthologue of the
filaggrin gene had not been annotated in public data-
bases. Therefore, the PCR primer set used for RT qPCR
(Table 1) was designed from the conserved region of
human FLG [GenBank:NM_002016], mouse flg [Gen-
Bank: J03458, AF510860] and rat flg [GenBank:M21759]
using Primer Express software (Applied Biosystems, Fos-
ter City, CA, USA), and positioned within the last pre-
dicted exon of the canine gene. Two reference genes
were selected as being most suitable in RT qPCR studies
in canine skin: Ribosomal protein L8 (RPL8; GenBank
[XM_532360]) and Ribosomal protein S19 (RPS19; Gen-
Bank: [XM_533657]) [27]. Primer sequences (Table 1)
for these reference genes were available from a previous
study [29]. The specificity of all primers was checked
using Blast [30], and results were confirmed by detec-
tion of a single band of the expected product size on
agarose gel electrophoresis and sequencing of PCR pro-
ducts. All primer sequences were synthesized by Gene-
Works (Hindmarsh, SA, Australia).
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Amplification efficiency (E) for each gene was deter-
mined using serial a modified delta cycle threshold (Ct)
method [31]; the linearity of the curve was verified from
the R2 coefficient. Efficiency (E = (10 (-1/-slope) - 1) ×
100%) varied between 78% (RPS19) and 110% (filaggrin)
and the R2 coefficient was greater than 0.99 for all
genes. GeNorm [32] and Bestkeeper [33] revealed simi-
lar expression stability for both reference genes; however
RPL8 was selected for gene expression normalization
due to its superior amplification efficiency (100%), and
lowest coefficient of variance (6.02 ± 1.30).
The reactions were run on an ABI 7,900 HT Fast
Real-Time PCR System (Applied Biosystems, Foster
City, CA, USA) and consisted of equal amounts of
cDNA (equivalent to 4 ng of total RNA), 5 μl of
2xSYBR Green I Master Mix (Applied Biosystem, Foster
City, CA, USA) and 1 μl of forward and reverse primers
(400 nm for filaggrin and RPL8 and 300 nm for RPS19).
The cycling conditions were at 95°C for 10 min, fol-
lowed by 45 cycles of 15 s at 95°C, and 90 s at 55°C.
The specificity of the amplified products was confirmed
by a melting curve analysis. Each sample was run in tri-
plicate and results were documented as Ct, using a 0.2
detection threshold for all assays.
Data were analysed by the Sequence Detection Sys-
tems software version 2.2.2 (Applied Biosystems, Foster
City, CA, USA). Mean normalized expression (MNE)
and standard error (SE) were calculated as described in
[34]. The mean SE between triplicates was 8.61% (range
3.30 to 14.71%).
Statistical analysis
Data were entered in an Excel® spreadsheet (Microsoft
Corporation, Redmond, DC, USA). All statistical ana-
lyses were carried out within the R statistical computing
environment [35]. Mann-Whitney test was used to com-
pare filaggrin MNE values between non-lesional skin of
atopic and non-atopic dogs. Additionally, the effect of
sex, age and breed on filaggrin MNE values was investi-
gated using ANOVA and regression models. The level
of statistical significance was set at 0.05.
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